Skip to main content
. 2020 Apr 21;64(5):e02267-19. doi: 10.1128/AAC.02267-19

FIG 3.

FIG 3

Study design with crystalline ribavirin-PRINT-IP (cohort B, multiple dose; 8 participants [6 active; 2 placebo]).